The phrase "actionable for identifying" is correct and usable in written English.
It can be used in contexts where you want to describe something that can be acted upon to help identify a particular issue or element.
Example: "The data collected from the survey is actionable for identifying trends in customer preferences."
Alternatives: "practical for identifying" or "usable for identifying".
The NIH Brain Initiative and Human Connectome Project, coupled with rapidly evolving systems biology and machine learning approaches for analyzing high-throughput genetic, transcriptomic and epigenetic data, hold promise for identifying actionable biological processes and gene networks that underlie HAND.
Such surveys of large cohorts of the microsatellite genomes of the affected individuals and the matched "healthy" populations could be a platform for identifying clinically actionable risk diagnostics, companion diagnostics, and drug targets when applied to complex multigenic diseases for which disease severity, therapy response, and other metadata are known.
In order to apply imaging biomarkers for identifying the genotype or phenotype of pancreatic cancer, clinically actionable mutations need to be identified.
In both IHC analyses (conducted for the entire cohort) and MA analyses (conducted for 17 patients), at least one actionable biomarker was identified for each patient (IHC: median, 4; range, 1 6; MA: median, 8; range, 3 20).
To determine the radiation risk to a child undergoing trauma evaluation with chest computed tomography (CCT) for every clinically actionable injury identified.
Overall, at least one actionable biomarker was identified for each patient (median: 8.0; range: 1 22).
Overall, at least one (median, 5.5; range, 1 13) actionable target was identified for each patient (median, 5.5; range, 1 13).
No studies had qualitatively investigated this practice and, in taking an exploratory approach, several actionable issues were identified for practice and ongoing research.
Overall, 53 out of 93 (57%) patients were allocated to 58 clinical trials between October 2012 and June 2013; 29 out of 53 patients (55%) who participated in clinical trials had trials suggested based on a relevant mechanism of action for the identified 'actionable' mutation (Table 5), whereas 29 out of 63 (46%) patients with identified actionable mutations participated in matched trials.
We started with a list of actionable variants identified by CPIC, and added disease genes of interest for our cohort.
Twentypercentt of cases had potentially actionable mutations identified.
